-
市场
-
产品
-
资讯
-
Moo社区
-
课堂
-
查看更多
-
功能介绍
-
费用费用透明，无最低余额限制
投资选择、功能介绍、费用相关信息由Moomoo Financial Inc.提供
- English
- 中文繁體
- 中文简体
- 深色
- 浅色
Mersana Therapeutics (NASDAQ:MRSN) Shares Up 3.7%
Mersana Therapeutics (NASDAQ:MRSN) Shares Up 3.7%
Mersana Therapeutics, Inc. (NASDAQ:MRSN – Get Rating)'s share price shot up 3.7% on Friday . The stock traded as high as $6.66 and last traded at $6.66. 2,607 shares were traded during mid-day trading, a decline of 100% from the average session volume of 1,150,149 shares. The stock had previously closed at $6.42.
Wall Street Analysts Forecast Growth
Several brokerages recently weighed in on MRSN. Robert W. Baird boosted their price objective on shares of Mersana Therapeutics from $18.00 to $20.00 and gave the stock an "outperform" rating in a research note on Tuesday, August 9th. Wedbush reaffirmed an "outperform" rating on shares of Mersana Therapeutics in a research report on Tuesday, August 9th. Finally, SVB Leerink upped their price target on shares of Mersana Therapeutics from $13.00 to $14.00 and gave the company an "outperform" rating in a research report on Tuesday, August 9th.
Get Mersana Therapeutics alerts:Mersana Therapeutics Trading Up 5.9 %
The company has a current ratio of 3.32, a quick ratio of 3.32 and a debt-to-equity ratio of 0.18. The stock's 50-day simple moving average is $6.85 and its 200 day simple moving average is $5.03.
Mersana Therapeutics (NASDAQ:MRSN – Get Rating) last issued its quarterly earnings results on Monday, August 8th. The company reported ($0.55) EPS for the quarter, missing analysts' consensus estimates of ($0.50) by ($0.05). The firm had revenue of $4.28 million for the quarter, compared to the consensus estimate of $3.18 million. Mersana Therapeutics had a negative net margin of 3,057.88% and a negative return on equity of 140.57%. As a group, sell-side analysts predict that Mersana Therapeutics, Inc. will post -1.69 EPS for the current year.Hedge Funds Weigh In On Mersana Therapeutics
A number of institutional investors and hedge funds have recently made changes to their positions in MRSN. Victory Capital Management Inc. bought a new position in shares of Mersana Therapeutics during the 1st quarter worth about $36,000. Quantbot Technologies LP bought a new position in shares of Mersana Therapeutics during the 1st quarter worth about $37,000. Washington University bought a new position in shares of Mersana Therapeutics during the 2nd quarter worth about $43,000. Virtu Financial LLC bought a new position in shares of Mersana Therapeutics during the 1st quarter worth about $53,000. Finally, Point72 Hong Kong Ltd bought a new position in shares of Mersana Therapeutics during the 4th quarter worth about $57,000. Institutional investors own 95.12% of the company's stock.
About Mersana Therapeutics
(Get Rating)
Mersana Therapeutics, Inc, a clinical stage biopharmaceutical company, develops antibody drug conjugates (ADC) for cancer patients with unmet need. It develops XMT-1592, a Dolasynthen ADC targeting NaPi2b-expressing tumor cells, which is in phase I clinical trial for the treatment of ovarian cancer and NSCLC adenocarcinoma.
Recommended Stories
- Get a free copy of the StockNews.com research report on Mersana Therapeutics (MRSN)
- This Is A Memorable Time To Buy Into Micron Technology
- Declining Profits Challenge the CarMax Value Proposition
- Let Paychex Stock Work Hard For You
- Thor Industries Hammers Out A Bottom
- How Does Keurig Dr Pepper Compare To Larger Rivals Coke & Pepsi?
Receive News & Ratings for Mersana Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Mersana Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
Mersana Therapeutics, Inc. (NASDAQ:MRSN – Get Rating)'s share price shot up 3.7% on Friday . The stock traded as high as $6.66 and last traded at $6.66. 2,607 shares were traded during mid-day trading, a decline of 100% from the average session volume of 1,150,149 shares. The stock had previously closed at $6.42.
默萨纳治疗公司(纳斯达克代码：MRSN-GET Rating)股价周五飙升3.7%，盘中一度涨至6.66美元，最新报6.66美元。午盘成交量为2,607股，较1,150,149股的平均成交量下跌100%。此前该股收盘价为6.42美元。
Wall Street Analysts Forecast Growth
华尔街分析师预测经济增长
Several brokerages recently weighed in on MRSN. Robert W. Baird boosted their price objective on shares of Mersana Therapeutics from $18.00 to $20.00 and gave the stock an "outperform" rating in a research note on Tuesday, August 9th. Wedbush reaffirmed an "outperform" rating on shares of Mersana Therapeutics in a research report on Tuesday, August 9th. Finally, SVB Leerink upped their price target on shares of Mersana Therapeutics from $13.00 to $14.00 and gave the company an "outperform" rating in a research report on Tuesday, August 9th.
几家券商最近加入了对MRSN的看法。罗伯特·W·贝尔德在8月9日星期二的一份研究报告中将Mersana治疗公司的股票目标价从18.00美元上调至20.00美元，并给予该股“跑赢大盘”的评级。韦德布什在8月9日星期二的一份研究报告中重申了对Mersana治疗公司股票的“跑赢大盘”评级。最后，SVB Leerink在8月9日星期二的一份研究报告中将Mersana Treeutics的股票目标价从13.00美元上调至14.00美元，并给予该公司“跑赢大盘”的评级。
Mersana Therapeutics Trading Up 5.9 %
Mersana治疗公司股价上涨5.9%
The company has a current ratio of 3.32, a quick ratio of 3.32 and a debt-to-equity ratio of 0.18. The stock's 50-day simple moving average is $6.85 and its 200 day simple moving average is $5.03.
该公司的流动比率为3.32，速动比率为3.32，债务权益比率为0.18。该股的50日简单移动均线切入位为6.85美元，200日简单移动均线切入位为5.03美元。
Hedge Funds Weigh In On Mersana Therapeutics
对冲基金入股Mersana Treeutics
A number of institutional investors and hedge funds have recently made changes to their positions in MRSN. Victory Capital Management Inc. bought a new position in shares of Mersana Therapeutics during the 1st quarter worth about $36,000. Quantbot Technologies LP bought a new position in shares of Mersana Therapeutics during the 1st quarter worth about $37,000. Washington University bought a new position in shares of Mersana Therapeutics during the 2nd quarter worth about $43,000. Virtu Financial LLC bought a new position in shares of Mersana Therapeutics during the 1st quarter worth about $53,000. Finally, Point72 Hong Kong Ltd bought a new position in shares of Mersana Therapeutics during the 4th quarter worth about $57,000. Institutional investors own 95.12% of the company's stock.
一些机构投资者和对冲基金最近改变了他们在MRSN的头寸。胜利资本管理公司在第一季度购买了价值约3.6万美元的Mersana治疗公司的新股票头寸。Quantbot Technologies LP在第一季度购买了Mersana Treateutics的新头寸，价值约3.7万美元。华盛顿大学在第二季度购买了Mersana Treeutics的新头寸，价值约43,000美元。Virtu Financial LLC在第一季度购买了Mersana Treeutics的新头寸，价值约53,000美元。最后，Point72 Hong Kong Ltd在第四季度购买了Mersana Treeutics的新股票头寸，价值约57,000美元。机构投资者持有该公司95.12%的股票。
About Mersana Therapeutics
关于Mersana Treeutics
(Get Rating)
(获取评级)
Mersana Therapeutics, Inc, a clinical stage biopharmaceutical company, develops antibody drug conjugates (ADC) for cancer patients with unmet need. It develops XMT-1592, a Dolasynthen ADC targeting NaPi2b-expressing tumor cells, which is in phase I clinical trial for the treatment of ovarian cancer and NSCLC adenocarcinoma.
Mersana治疗公司是一家临床阶段生物制药公司，为未得到满足需求的癌症患者开发抗体药物结合物(ADC)。它开发了XMT-1592，一种针对NaPi2b表达肿瘤细胞的Dolasynten ADC，正在进行治疗卵巢癌和NSCLC腺癌的I期临床试验。
Recommended Stories
推荐故事
- Get a free copy of the StockNews.com research report on Mersana Therapeutics (MRSN)
- This Is A Memorable Time To Buy Into Micron Technology
- Declining Profits Challenge the CarMax Value Proposition
- Let Paychex Stock Work Hard For You
- Thor Industries Hammers Out A Bottom
- How Does Keurig Dr Pepper Compare To Larger Rivals Coke & Pepsi?
- 免费获取StockNews.com关于Mersana治疗公司(MRSN)的研究报告
- 这是买入美光科技的难忘时刻
- 利润下降对CarMax价值主张的挑战
- 让Paychex股票为您努力工作
- 雷神工业走出谷底
- Keurig Dr Pepper与规模更大的竞争对手可口可乐(Coke&Pepsi)相比如何？
Receive News & Ratings for Mersana Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Mersana Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
接受Mersana治疗日报的新闻和评级-在下面输入您的电子邮件地址，通过MarketBeat.com的免费每日电子邮件时事通讯接收对Mersana Treeutics和相关公司的最新新闻和分析师评级的每日简要摘要。
moomoo是Moomoo Technologies Inc.公司提供的金融信息和交易应用程序。
在美国，moomoo上的投资产品和服务由Moomoo Financial Inc.提供，一家受美国证券交易委员会（SEC）监管的持牌主体。 Moomoo Financial Inc.是金融业监管局（FINRA）和证券投资者保护公司（SIPC）的成员。
在新加坡，moomoo上的投资产品和服务是通过Moomoo Financial Singapore Pte. Ltd.提供，该公司受新加坡金融管理局（MAS）监管(牌照号码︰CMS101000) ，持有资本市场服务牌照 (CMS) ，持有财务顾问豁免（Exempt Financial Adviser）资质。本内容未经新加坡金融管理局的审查。
在澳大利亚，moomoo上的金融产品和服务是通过Futu Securities (Australia) Ltd提供，该公司是受澳大利亚证券和投资委员会(ASIC)监管的澳大利亚金融服务许可机构（AFSL No. 224663）。请阅读并理解我们的《金融服务指南》、《条款与条件》、《隐私政策》和其他披露文件，这些文件可在我们的网站 https://www.moomoo.com/au中获取。
在加拿大，通过moomoo应用提供的仅限订单执行的券商服务由Moomoo Financial Canada Inc.提供，并受加拿大投资监管机构（CIRO）监管。
在马来西亚，moomoo上的投资产品和服务是通过Moomoo Securities Malaysia Sdn. Bhd. 提供，该公司受马来西亚证券监督委员会（SC）监管(牌照号码︰eCMSL/A0397/2024) ，持有资本市场服务牌照 (CMSL) 。本内容未经马来西亚证券监督委员会的审查。
Moomoo Technologies Inc., Moomoo Financial Inc., Moomoo Financial Singapore Pte. Ltd., Futu Securities (Australia) Ltd, Moomoo Financial Canada Inc.,和Moomoo Securities Malaysia Sdn. Bhd.是关联公司。
风险及免责提示
moomoo是Moomoo Technologies Inc.公司提供的金融信息和交易应用程序。
在美国，moomoo上的投资产品和服务由Moomoo Financial Inc.提供，一家受美国证券交易委员会（SEC）监管的持牌主体。 Moomoo Financial Inc.是金融业监管局（FINRA）和证券投资者保护公司（SIPC）的成员。
在新加坡，moomoo上的投资产品和服务是通过Moomoo Financial Singapore Pte. Ltd.提供，该公司受新加坡金融管理局（MAS）监管(牌照号码︰CMS101000) ，持有资本市场服务牌照 (CMS) ，持有财务顾问豁免（Exempt Financial Adviser）资质。本内容未经新加坡金融管理局的审查。
在澳大利亚，moomoo上的金融产品和服务是通过Futu Securities (Australia) Ltd提供，该公司是受澳大利亚证券和投资委员会(ASIC)监管的澳大利亚金融服务许可机构（AFSL No. 224663）。请阅读并理解我们的《金融服务指南》、《条款与条件》、《隐私政策》和其他披露文件，这些文件可在我们的网站 https://www.moomoo.com/au中获取。
在加拿大，通过moomoo应用提供的仅限订单执行的券商服务由Moomoo Financial Canada Inc.提供，并受加拿大投资监管机构（CIRO）监管。
在马来西亚，moomoo上的投资产品和服务是通过Moomoo Securities Malaysia Sdn. Bhd. 提供，该公司受马来西亚证券监督委员会（SC）监管(牌照号码︰eCMSL/A0397/2024) ，持有资本市场服务牌照 (CMSL) 。本内容未经马来西亚证券监督委员会的审查。
Moomoo Technologies Inc., Moomoo Financial Inc., Moomoo Financial Singapore Pte. Ltd., Futu Securities (Australia) Ltd, Moomoo Financial Canada Inc.,和Moomoo Securities Malaysia Sdn. Bhd.是关联公司。
- 分享到weixin
- 分享到qq
- 分享到facebook
- 分享到twitter
- 分享到微博
- 粘贴板
使用浏览器的分享功能，分享给你的好友吧